CDK4 and glioblastoma: Some studies have shown that the CDK4/6 inhibitor can overcome temozolomide resistance and reduce the number of inhibitory M2-macrophages in glioblastoma (23), although the phase II clinical trial for recurrent glioblastoma patients has failed (24).